Millions of Americans are set to face skyrocketing health care premiums as ACA subsidies expire. A bipartisan group of senators is working on a compromise to extend these critical tax credits, potentially easing financial burdens for many families.
In a groundbreaking move, President Trump has forged agreements with major pharmaceutical companies to significantly lower drug prices for Americans, ensuring access to affordable medications for chronic conditions.
As ACA subsidies near expiration, the Senate's upcoming vote on health care bills is expected to fail, leaving millions at risk of skyrocketing premiums. Both parties are at odds, with urgent calls for a three-year extension.
This Thanksgiving is shaping up to be one of the coldest in years, with forecasts of snow and frigid temperatures potentially disrupting travel plans for millions of Americans. The National Weather Service warns of a polar vortex expanding southward as AAA predicts record holiday traffic.
In a dramatic turn of events, the Supreme Court has intervened in the Trump administration's ongoing struggle over SNAP benefits funding, delaying full food assistance for millions as legal challenges unfold.
The Supreme Court has extended a temporary order allowing the Trump administration to delay full food stamp payments, leaving millions of Americans, including children, in need as the government shutdown continues.
The USDA is set to comply with a federal judge's order to provide full food benefits to 42 million Americans despite a government shutdown. Confusion remains as the Justice Department appeals the decision.
In a groundbreaking move, the Trump administration has announced new agreements with Novo Nordisk and Eli Lilly to significantly reduce the cost of GLP-1 medications for American patients, including those on Medicare. With prices set to drop dramatically, millions will soon benefit from affordable access to essential treatments.
In a landmark ruling, a federal judge mandates the Trump administration to fully fund SNAP benefits for November, rejecting partial funding during the government shutdown. Millions of Americans at risk of hunger will now receive necessary support.
In a groundbreaking move, President Trump announces deals with Eli Lilly and Novo Nordisk to reduce obesity drug prices, making treatments more accessible for millions of Americans. Medicare coverage for GLP-1 drugs starts in 2026, changing the landscape of obesity treatment.